This is why I've sat on the sidelines.
For many companies, stem cells have been a case of "I've got this neat thing, let's see if it works on something", which is sometimes a viable strategy but requires a lot of studies and May amount to nothing.
A concern I have going forward is how they've mentioned the Novartis partnership at the bottom of the announcement today, specifically the Hart-Scott-Rodino antitrust improvements act.
I don't know much about the act but I did some googling.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-496
-
- There are more pages in this discussion • 580 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $21.32M | 17.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5460 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 978 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |